Cancer drugs approved based on biomarkers and not tumor type - FDA approval of pembrolizumab for mismatch repair-deficient solid cancers

Vinay Prasad, Victoria Kaestner, Sham Mailankody

Research output: Contribution to journalShort survey

21 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)157-158
Number of pages2
JournalJAMA oncology
Volume4
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

DNA Mismatch Repair
Tumor Biomarkers
Pharmaceutical Preparations
Neoplasms
pembrolizumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cancer drugs approved based on biomarkers and not tumor type - FDA approval of pembrolizumab for mismatch repair-deficient solid cancers. / Prasad, Vinay; Kaestner, Victoria; Mailankody, Sham.

In: JAMA oncology, Vol. 4, No. 2, 01.02.2018, p. 157-158.

Research output: Contribution to journalShort survey

@article{3941756adf574048a53dd44aa512957b,
title = "Cancer drugs approved based on biomarkers and not tumor type - FDA approval of pembrolizumab for mismatch repair-deficient solid cancers",
author = "Vinay Prasad and Victoria Kaestner and Sham Mailankody",
year = "2018",
month = "2",
day = "1",
doi = "10.1001/jamaoncol.2017.4182",
language = "English (US)",
volume = "4",
pages = "157--158",
journal = "JAMA oncology",
issn = "2374-2437",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - Cancer drugs approved based on biomarkers and not tumor type - FDA approval of pembrolizumab for mismatch repair-deficient solid cancers

AU - Prasad, Vinay

AU - Kaestner, Victoria

AU - Mailankody, Sham

PY - 2018/2/1

Y1 - 2018/2/1

UR - http://www.scopus.com/inward/record.url?scp=85045592392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045592392&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2017.4182

DO - 10.1001/jamaoncol.2017.4182

M3 - Short survey

VL - 4

SP - 157

EP - 158

JO - JAMA oncology

JF - JAMA oncology

SN - 2374-2437

IS - 2

ER -